The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1β-driven IL-6 secretion in glioblastoma cells
Gurgis, F M S, Yeung, Y T, Tang, M X M, Heng, B, Buckland, M, Ammit, A J, Haapasalo, J, Haapasalo, H, Guillemin, G J, Grewal, T, Munoz, L
Published in Oncogene (28.05.2015)
Published in Oncogene (28.05.2015)
Get full text
Journal Article
The Mapk-activated protein Kinase 2 (MK2) inhibitor CMPD1 is a novel microtubule targeting agent for Glioblastoma Therapy
Gurgis, F, Åkerfeldt, M, Wong, C, Heng, B, Guillemin, G.J, Chircop, M, Munoz, L
Published in Clinical therapeutics (01.08.2015)
Published in Clinical therapeutics (01.08.2015)
Get full text
Journal Article
The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1[beta]-driven IL-6 secretion in glioblastoma cells
Gurgis, F M S, Yeung, Y T, Tang, M X M, Heng, B, Buckland, M, Ammit, A J, Haapasalo, J
Published in Oncogene (01.05.2015)
Published in Oncogene (01.05.2015)
Get full text
Journal Article
Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2
Gurgis, Fms, Åkerfeldt, M C, Heng, B, Wong, C, Adams, S, Guillemin, G J, Johns, T G, Chircop, M, Munoz, L
Published in Cell death discovery (07.09.2015)
Published in Cell death discovery (07.09.2015)
Get full text
Journal Article